Product Code: GVR-2-68038-627-1
ADME Toxicology Testing Market Growth & Trend:
The global ADME toxicology testing market size is expected to generate a revenue of USD 19.21 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 10.2% during the forecast period. Factors such as increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.
Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is used to test toxic reactions caused by molecules in clinical trials on factors and systemic reactions such as chemical, pharmaceutical, and genetic. These toxicology testing procedures help in effective drug development, which limits or prevents toxic reactions to the body when administered. Toxicity levels are decided on the results of a series of tests conducted in near-natural conditions, which represent almost real-time reactions between the drug and the host.
As of 2017, approximately 43.0% of ADME toxicology testing areas carried out are based on cell culture tech. Cell culture technology is adopted widely owing to advantages such as near-natural conditions and accurate results obtained at a cellular level.
These assays are conducted for several types of toxic reactions or systems where toxic reactions might take place. Some of the toxicity tests are systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicities that might result in living tissue. Advancements in testing methods are underway and this trend is likely to be picked up by many companies developing drug molecules. This will speed up the drug discovery process and boost the market growth.
ADME Toxicology Testing Market Report Highlights:
- The market is driven by an increasing ratio of late-stage drug failures, resulting in loss of valuable time and investment for drug development. Growth and increasing adoption of OMICS technology is also expected to boost revenue generation in the coming years
- North America is the largest market for ADME toxicology testing owing to the presence of a large number of pharmaceutical companies competing for the commercial launch of novel molecules
- Developing regions of Asia Pacific and Latin America are set to grow considerably as many multinational and local players are striving to enter the market. They are also looking to improve their hold in markets that present innovation and growth opportunities
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Technology
- 1.1.2. Application
- 1.1.3. Method
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. Method outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. ADME Toxicology Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. ADME Toxicology Testing Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. ADME Toxicology Testing: Technology Estimates & Trend Analysis
- 4.1. ADME Toxicology Testing Market: Key Takeaways
- 4.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Cell Culture
- 4.3.1. Cell Culture market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. High Throughput
- 4.4.1. High throughput market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Molecular Imaging
- 4.5.1. Molecular imaging market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. OMICS Technology
- 4.6.1. OMICS technology market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. ADME Toxicology Testing Market: Application Estimates & Trend Analysis
- 5.1. ADME Toxicology Testing Market: Key Takeaways
- 5.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Systemic Toxicity
- 5.3.1. Systemic toxicity market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Renal Toxicity
- 5.4.1. Renal toxicity market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Hepatotoxicity
- 5.5.1. Hepatotoxicity market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Neurotoxicity
- 5.6.1. Neurotoxicity market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Other Toxicities
- 5.7.1. Other toxicities market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. ADME Toxicology Testing Market: Method Estimates & Trend Analysis
- 6.1. ADME Toxicology Testing Market: Key Takeaways
- 6.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Cellular Assay
- 6.3.1. Cellular assay market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Biochemical Assay
- 6.4.1. Biochemical assay market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. In-Silica
- 6.5.1. In-silica market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Ex-vivo
- 6.6.1. Ex-vivo market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. ADME Toxicology Testing Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. ADME Toxicology Testing Market by Region: Key Takeaway
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Sweden
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Norway
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Thermo Fisher Scientific Inc.
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Promega Corporation
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Agilent Technologies, Inc.
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Curia Global, Inc.
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Dassault Systemes
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Beckman Coulter, Inc., (Danaher)
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Catalent, Inc
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Charles River Laboratories
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Labcorp Drug Development
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Eurofins Scientific
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. GE HealthCare
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.12. Miltenyi Biotec
- 8.2.12.1. Company overview
- 8.2.12.2. Financial performance
- 8.2.12.3. Product benchmarking
- 8.2.12.4. Strategic initiatives
- 8.2.13. IQVIA Inc
- 8.2.13.1. Company overview
- 8.2.13.2. Financial performance
- 8.2.13.3. Product benchmarking
- 8.2.13.4. Strategic initiatives